


CLAIMS

1. Compounds of formula I



wherein

n is an integer from 1 to 4

R₁ is a hydrogen atom, hydroxyl group or lower C₁₋₆ alkoxy group

R₂ is a hydrogen atom or a straight or branched lower C₁₋₆ alkyl group

X is hydrogen, fluorine, chlorine, bromine, hydroxyl group, trifluoromethyl group, 3,4-di-Cl, 2,4-di-Cl or lower C₁₋₆ alkoxy group

and enantiomers, diastereoisomers or racemates thereof or the physiologically acceptable acid addition salts thereof.

2. The compounds according to claim 1 in which n is an integer 2, R₁ is a hydroxyl group, R₂ a methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl group and X is a hydrogen atom or phenyl disubstituted with 2 chlorine atoms in the positions 3 and 4 or in the positions 2 and 4

3. The compounds according to claims 1 and 2 in which R₁ is a hydroxyl group in the RS configuration.


4. 1-(3-pyridyl)-2-(N-(2-(3,4-dichlorophenyl)ethyl)-N-propylamino)ethanol and a dihydrobromide salt thereof.
5. 1-(3-pyridyl)-2-(N-(2-phenylethyl)-N-propylamino)ethanol and a dihydrobromide salt thereof.
6. 1-(3-pyridyl)-2-(N-(2-(3,4-dichlorophenyl)ethyl)-N-methylamino)ethanol and a dihydrobromide salt thereof.
7. 1-(4-pyridyl)-2-(N-(2-(3,4-dichlorophenyl)-N-methylamino)ethanol and a dihydrobromide salt thereof.
8. The compounds of formula I according to any of claims 1 to 7 and the physiologically acceptable acid addition salts thereof as the ligands of sigma receptors for inhibiting cholesterol biosynthesis in the treatment of hypercholesterolemia and hyperlipemia in humans.
9. The pharmaceutical compositions comprising the compound of formula I according to any of claims 1 to 7 and the physiologically acceptable acid addition salts thereof.
10. Use of the compounds of formula I according to any claims 1 to 7 and the physiologically acceptable acid addition salts thereof as the ligands of sigma receptors for inhibiting cholesterol biosynthesis for preparation of the pharmaceutical compositions for treating hypercholesterolemia and hyperlipemia in humans.
11. The process for preparation of the compounds of formula I according to any of claims 1 to 7 which process comprises
 - a) alkylating secondary amines of formula VI



VI


wherein

R_2 is as defined above in formula I and Z is a group



in which X is as defined above in formula I,

with pyridyloxirane of formula VII



VII

and, if desired, the obtained compounds of formula I are converted into the salt or

b) alkylating primary amines of formula VIII




VIII

wherein R_2 is as defined above in formula I,

with pyridyloxirane of formula VII



to intermediate compounds of formula IX




wherein R_2 is as define above in formula I,

and condensing with the derivatives of phenylacetic acid of formula X



wherein Z is as defined above,

to intermediate compounds of formula XI



and reducing them to the title compounds of formula I, and, if desired, converting them into the salt.